Case Studies
Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…
Read More
In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering. …
Read More
Inspire Medical became a LifeSci Advisors client pre-IPO. The teams collaborated to develop and execute a robust, best-in-class investor relations program to engage the investment community The Process A successful strategically timed KOL event before going live on the IPO was well attended by investors and sell-side analysts, attracting potential investors new to the story…
Read More